Benefits of Mammography Outweigh Harms In Women with Increased Risk, Starting at Age 40
ASCO Publishes Guidelines For Dosing Chemotherapy Correctly in Obese Patients
Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival
Researchers Link Cancer Risk And DMPA Birth Control Use
Breast-Conserving Procedures Lead To Frequent Follow-up Care
False-Positive Mammograms Can Indicate Higher Cancer Risk
Proposed Surveillance Model Aims To Reduce Post-Treatment Pain
Adding Avastin Did Not Improve Standard Chemotherapy Regimen
Ibrutinib Demonstrates Responses In Large B-Cell Lymphomas
Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial
Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options
Translplants Not Best Choice in Subset of ALL Patients
PET Response Can Predict Increased Survival In Patients
Cancer Incidence Rates Climb In HIV-Positive Female Populations
Technology Isolates and Recovers Circulating Liver Tumor Cells
Survey Shows That One-Third Of Patients Are Undertreated
Trials Approved by NCI CTEP For the Month of April
FDA Approves Votrient For Soft Tissue Sarcomas
Trending Stories
- NIH Director Jay Bhattacharya launches a podcast
- As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- “Forward funding” NIH budget plan would make competing for grants much harder
- Optimizing dosing of expensive and toxic oncology drugs: Making America healthier
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”
